IDEX Corp
✦ Quant Fair Value how this is computed
- Implied fair-value range of 169.55-213.29, from this stock's own trailing 5-year average P/E applied to trailing EPS.
- Current price is +14.7% above the average-multiple fair value of 191.42.
Valuation each multiple against its own 5-year range
Vs. peers Specialty Industrial Machinery
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| IDEX Corp (IEX) | 16.13B | 30.51 | 4.02 | 1.64% |
| GE Vernova (GEV) | 185.10B | 18.36 | 16.26 | 0.25% |
| Eaton (ETN) | 120.95B | 31.01 | 5.77 | 1.39% |
| Parker Hannifin (PH) | 109.94B | 29.95 | 6.88 | 0.87% |
| Emerson Electric (EMR) | 82.80B | 31.51 | 3.99 | 1.47% |
| Illinois Tool Works (ITW) | 77.75B | 24.40 | 24.75 | 2.39% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 3.8% below Morningstar's fair value estimate.
Analyst note
Idex increased third-quarter adjusted earnings per share by 15% to $2.33 from the prior year. Management raised its guidance and now anticipates full-year adjusted EPS of $8.91-$8.96, up from $8.70-$8.85.
Why it matters: We think Idex’s results demonstrate solid execution and underscore its strength. Idex delivered a positive price-cost spread on a dollar basis despite persistent cost inflation. Adjusted EBITDA margin expanded 50 basis points year over year to 27.8%, above management’s guidance range of 27%-27.5%. The company specializes in mission-critical equipment that typically makes up a small part of a customer’s total bill of materials, allowing Idex to command premium pricing.
The bottom line: We’ve raised our fair value estimate for wide-moat-rated Idex to $228 per share from $226, mostly due to the time value of money. We see the name as fairly valued at current levels. Third-quarter organic sales were up 8% year over year, driven by broad-based growth across all three segments: 13% in health and science technologies, 4% in fluid and metering technologies, and 6% in fire and safety and diversified products. Organic orders increased 13%, including 21% growth in health and science technologies, showing strong momentum heading into the fourth quarter. We expect the health and science technologies segment to capitalize on opportunities in data center, semiconductor, and space and defense end markets.
BLANK PAGE
Fair value
We’ve raised our fair value estimate for wide-moat-rated Idex to $228 per share from $226, mostly due to the time value of money. Management raised its guidance and now anticipates full-year adjusted EPS of $8.91 to $8.96, up from $8.70 to $8.85 previously.
We model a roughly 6% organic revenue CAGR during our five-year explicit forecast period. In the long run, we view Idex as a GDP-plus business, projecting organic revenue growth that outpaces the industrial production growth rate by approximately 1%-2%. This is driven by ongoing investments in R&D, which fuel revenue growth through new product introductions, entry into adjacent markets, and market share gains. Additionally, we expect that management will continue to invest in M&A, and our model incorporates meaningful acquisitions, helping the company reach a roughly 9% total growth rate from 2025 through 2030. In our base-case scenario, we model an average enterprise value/sales multiple of 2.5 times for acquisitions.
We project adjusted EBITDA margins averaging around 28% over the next five years, roughly 50 basis points above the average adjusted EBITDA margins during the prior five years, as we expect the company to benefit from higher volumes driving increased profitability in the long run. We model a roughly 29% adjusted EBITDA margin for our midcycle assumption. We assume an 8.2% weighted average cost of capital and a 22% long-run effective tax rate in our model.
Economic moat
We believe that Idex has dug a wide moat based on customer switching costs and intangible assets. Idex differentiates itself by producing highly engineered products (including pumps, valves, flow meters, and fluidic systems) for a variety of niche markets, where it typically holds the number-one or -two market share position. The company’s Lean manufacturing capabilities and flexible operations allow it to thrive in a high-mix and low-volume environment, offering customers a wide array of configurable and customizable solutions.
Idex has a large installed base that is protected by customer switching costs. Equipment manufactured by Idex often performs mission-critical functions in areas where the cost of failure is high. For example, ADS and iPek solutions are used for monitoring wastewater collection systems, Band-It fastening solutions are used on submarines and space shuttles (and have even been used on the International Space Station and Mars rover), and Hurst Jaws of Life are used to rescue people from car accidents. As such, any product failures could lead to costly business disruptions, environmental hazards, safety risks, or even loss of life. Idex’s long-standing reputation for quality and record of safety allow it to retain customer loyalty in these specialized and difficult applications where the margin for error is low. Furthermore, considering that Idex’s equipment often accounts for a fraction of a customer’s bill of materials but performs a vital function, we believe that customers are loath to switch to cheaper but less-proven alternatives, as the potential cost of failure (including unscheduled downtime and safety considerations) could far outweigh potential cost savings.
Idex’s large installed base drives a healthy stream of recurring revenue, which we estimate can constitute around 30%-40% of sales, depending on the business line. The constant wear and tear on the equipment results in steady demand for servicing and replacement parts, and aftermarket revenue tends to be relatively more stable and carry higher margins. In some areas of its business, Idex also benefits from long-term customer agreements. For example, the health and science technologies segment has multiyear contracts to supply components to original equipment manufacturers, and many businesses in Idex’s portfolio generate a part of their revenue through service agreements. Additionally, some of Idex’s businesses operate under a razor-and-blade model, where the installed base drives a steady stream of revenue from consumables (for instance, the health and science segment supplies microfluidic cartridges).
While new entrants have made attempts to capture aftermarket sales in more generic and commoditized industrials markets, we believe that Idex is relatively less vulnerable to the threat of new entrants given that it tends to operate in more niche markets. Its highly engineered and customizable parts are often difficult to replicate. Additionally, the high-mix and low-volume nature of its business creates a barrier to entry, as it would require competitors to match the breadth of Idex’s portfolio, as well as to replicate its network of relationships with customers and distributors, in order to establish the requisite scale to compete effectively. Idex has not ceded share in the aftermarket space, and we believe that its customer switching costs moat source remains intact.
Idex’s wide moat is also supported by intangible assets, including strong brands (for example, the name Jaws of Life has become synonymous with emergency rescue tools in the United States), patent portfolio, and reputation for quality and reliability. We believe the company maintains an adequate level of R&D spending, averaging approximately 3% of sales in recent years, roughly 1% more than its peers. Idex’s investments in innovation have allowed it to capture incremental market share gains through introductions of new and improved products, as well as entry into adjacent markets. For example, in 2012 the company launched the X-Smart automatic dispenser, a small-size and economical paint dispenser, that has helped Idex win market share, particularly in emerging economies. The firm has also expanded its offerings of hydraulic rescue tools with new battery-powered tools that are portable, such as eDraulic and StrongArm, which have helped Idex expand its market share and keep abreast of competition. A more recent example of Idex’s innovation is the 2019 introduction of the SAM Control System, an integrated system that manages a fire truck’s water flow and simplifies the job of the pump operator, thus minimizing the potential for error. Overall, we think Idex has done a respectable job refreshing its product portfolio to maintain its competitive position and keep rivals at bay.
Bull case
Idex has a portfolio of moaty businesses that have a leading share in niche end markets.
Idex generates strong free cash flows, which have averaged around 17.5% of sales during the past 10 years.
The acquisitions of Akron Brass and AWG, as well as new product introductions (including eDraulic and SAM), have reinforced Idex’s already strong competitive position in the fire and safety business.
Bear case
If industrial production remains sluggish, organic revenue growth may decelerate.
Idex relies on acquisitions to supplement its organic growth, and poor execution of its M&A strategy could destroy shareholder value.
Cost inflation, tariffs, and persistent strength in the US dollar could have an adverse impact on the firm’s profitability.
By Krzysztof Smalec, CFA
Quote time 2026-11-20 20:02:26 · For reference only, not investment advice and not tailored to your situation.
IDEX Corp discussion 0 comments